Albany, New York: Dupixent Lawsuits

Jed Dietrich, Esq., Recognized as a Best Lawyer and American Institute of Personal Injury Attorneys 10 Best Attorney, is Committed to Protecting the Rights of Breast Mesh Injury Victims Across Albany. If You or a Loved One Has Been Diagnosed with Cutaneous T-Cell Lymphoma (CTCL) After Taking Dupixent, Our Experienced Team of Attorneys Could Help You Collect the Evidence You Need to Obtain a Fair Settlement.

Dupixent is a prescription medication used to treat asthma and atopic dermatitis.

More than one million people worldwide have taken Dupixent at some point in their lives. Since its release in 2017, Dupixent has largely enjoyed a reputation as an effective and safe medication. However, scientists now believe that Dupixent could put patients at risk for cutaneous T-cell lymphoma, a rare and potentially aggressive cancer that mimics many of the same symptoms as eczema. Nobody understands why this relationship exists, but patients have already started to take action against Dupixent’s manufacturers, claiming they were never warned of the risk.

If you or a loved one has been diagnosed with cutaneous T-cell lymphoma or any of its subtypes after taking Dupixent, you could be entitled to significant compensation.

Since our founding in 2005, the Dietrich Law Firm P.C.’s experienced team of personal injury lawyers has helped our clients in Albany and throughout Upstate New York secure more than $300 million in damages money that they have used to eradicate medical debt, afford higher-quality cancer treatment, and plan for a better, healthier future.

We could help you, too.

Please send us a message online or call us today at 1-866-529-5334 to speak to a Dupixent cancer lawyer near Albany, schedule your free consultation, and find out how we could help you.

Dupixent is a type of biologic medication that was specifically engineered to reduce inflammation. Unlike common over-the-counter ointments used to treat eczema and other skin disorders, Dupixent is typically administered as an injection. It works from the inside out by targeting a select series of protein receptors. More specifically, Dupixent binds to the interleukin-4 alpha subunit, which inhibits signals from both the IL-4 and IL-3 proteins.

By inhibiting these receptors, Dupixent can help curb inflammation. This can prove beneficial in the treatment of conditions like asthma and eczema. In the case of asthma, reduced inflammation can help keep the airways open, preventing attacks from taking place and making them easier to handle when they do occur. Dupixent can also relieve eczema by controlling the inflammatory response that triggers outbreaks of scaly and itchy skin.

Dupixent is a relatively safe medication; it is also one of the most common first-line treatments for eczema and atopic dermatitis. However, medical researchers believe that Dupixent could have a serious downside. According to a growing body of research, people who take Dupixent have a significantly higher-than-average chance of developing and being diagnosed with cutaneous T-cell lymphoma (CTCL).

Cutaneous T-cell lymphoma is a rare type of cancer. Its most common subtypes include:

1. Mycosis fungoides. Mycosis fungoides is one of the most frequently diagnosed subtypes of CTCL. It primarily affects the skin and is less likely to metastasize and spread to other parts of the body than more aggressive forms of cancer. Most people who are diagnosed with mycosis fungoides can recover with a fast diagnosis and proper treatment.
2. Sezary syndrome. Sezary syndrome is a rarer but more serious subset of CTCL. Unlike mycosis fungoides, Sezary syndrome affects skin and blood cells. It is incurable and has a relatively low 5-year survival rate.

The use of Dupixent has been positively associated with an increased risk for both subtypes of CTCL. Nobody understands why this relationship exists. Some scientists have proposed that Dupixent’s effects on the immune system can make it more difficult to treat cutaneous T-cell lymphoma, in large part because Dupixent can effectively “mask” the early-warning signs of cancer. This is primarily because illnesses like mycosis fungoides can trigger symptoms that are nearly indistinguishable from eczema outbreaks.

Identifying cutaneous T-cell lymphoma is notoriously difficult, even for experienced doctors.

Part of the difficulty in diagnosing CTCL relates to the generality of its most common symptoms. These could include, but are not limited to, the following:

1. Patches of red, raised, or scaly skin;
2. Patches of skin with an abnormal pink, grey, red, or brown coloration;
3. Patches of skin that are noticeably lighter than the skin around them;
4. Lumps that form on the skin and burst open, sometimes repeatedly;
5. Enlarged or swollen lymph nodes;
6. Unexpected or unexplained hair loss;
7. Thickened skin on your palms or the soles of your feet; and
8. A full-body rash that is both itchy and scaly.

People who have eczema, in contrast, may also experience intense itching, inflamed and discolored patches of skin, and noticeable changes to the texture of their skin.

Scientists are not sure whether Dupixent causes, exacerbates, or accelerates cutaneous T-cell lymphoma, but most experts agree that an eczema or atopic dermatitis misdiagnosis can significantly delay the time it takes to positively identify and treat CTCL. This can lead to worse outcomes and longer recoveries.

Cutaneous T-cell lymphoma is not as aggressive as cancers like malignant mesothelioma, but that does not mean it is a minor condition. Treatment can be intensive and expensive.

Depending on the stage, severity, and location of the cancer, treatment may involve:

1. Prescription-strength ointments;
2. Chemotherapy;
3. Targeted light therapy;
4. Radiation therapy;
5. Immunotherapy; and
6. Bone marrow transplants.

If you have been diagnosed with CTCL, the treatment can be cost-prohibitive. Even with a good insurance plan, the cost of repeated therapies, recurring co-pays, and massive deductibles can strip away almost any family’s life savings. Furthermore, treatment does not always end when cancer goes into remission. You may also require physical rehabilitation or long-term care expenses that can accumulate even more quickly than medical debt, thrusting retirement plans and education funds into dire straits.

Under state and federal law, pharmaceutical companies must undergo an intensive series of steps before releasing new prescription medications. Even after a new medicine is tested and approved by the Food and Drug Administration, companies still have a responsibility to:

1. Investigate reported side effects;
2. Document verifiable complications; and
3. Update warning labels to reflect newly recognized risks.

Most people who have been prescribed Dupixent were never warned that their medication could cause, conceal, or worsen cutaneous T-cell lymphoma. If you or a loved one has been diagnosed with CTCL after taking Dupixent, you could be entitled to significant compensation.

A recognized U.S. News & World Report Best Law Firm, the Dietrich Law Firm P.C. knows what it takes to build a compelling, evidence-based case for compensation. Call Jed Dietrich, Esq., today at 1-866-529-5334 to speak to a Dupixent cancer lawyer near Albany and schedule your 100% free, no-obligation consultation as soon as possible.

Call the Dietrich Law Firm P.C. immediately at 1-866-529-5334 so that our aggressive, tenacious, and hardworking personal injury lawyers can fight to obtain the best result for your personal injury claim in Albany, New York. We are available 24 hours a day, 7 days a week, and there is never a fee until we WIN for you!